Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
26.48
+2.02 (8.26%)
Jul 30, 2026, 3:36 PM EDT - Market open
Castle Biosciences Revenue
Castle Biosciences had revenue of $83.68M in the quarter ending March 31, 2026, a decrease of -4.90%. This brings the company's revenue in the last twelve months to $339.92M, down -2.06% year-over-year. In the year 2025, Castle Biosciences had annual revenue of $344.23M with 3.66% growth.
Revenue (ttm)
$339.92M
Revenue Growth
-2.06%
P/S Ratio
2.31
Revenue / Employee
$360,849
Employees
942
Market Cap
803.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 344.23M | 12.16M | 3.66% |
| Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
| Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
| Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
| Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
| Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
| Dec 31, 2019 | 51.87M | 29.08M | 127.62% |
| Dec 31, 2018 | 22.79M | 9.03M | 65.67% |
| Dec 31, 2017 | 13.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Fulgent Genetics | 320.35M |
| Adaptive Biotechnologies | 308.08M |
| GRAIL | 156.12M |
CSTL News
- 8 days ago - Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference - PRNewsWire
- 15 days ago - Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - PRNewsWire
- 21 days ago - Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - PRNewsWire
- 4 weeks ago - Castle Biosciences’ i31-SLNB outperforms MIA nomogram in lymph node biopsy - TheFly
- 4 weeks ago - DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - PRNewsWire
- 5 weeks ago - Roth starts Castle Biosciences at Buy, notes quality revenue growth outlook - TheFly
- 5 weeks ago - Castle Biosciences initiated with a Buy at Roth Capital - TheFly
- 5 weeks ago - Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal - PRNewsWire